Do analysts recommend MESO or KYMR?

Kymera Therapeutics has a consensus target price of $117.14, indicating a potential upside of 19.22%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Kymera Therapeutics 1 Sell rating(s) 0 Hold rating(s) 21 Buy rating(s) 1 Strong Buy rating(s) 2.96

Does the media favor MESO or KYMR?

In the previous week, Kymera Therapeutics had 16 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for Kymera Therapeutics and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.34 beat Kymera Therapeutics' score of -0.12 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMVT or MESO?

Immunovant presently has a consensus target price of $37.33, indicating a potential downside of 0.76%. Given Immunovant's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunovant is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, IMVT or MESO?

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Mesoblast $17.20M 115.76 -$102.14M -$0.54 N/A

Is IMVT or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Mesoblast N/A N/A N/A

Does the media prefer IMVT or MESO?

In the previous week, Immunovant had 1 more articles in the media than Mesoblast. MarketBeat recorded 2 mentions for Immunovant and 1 mentions for Mesoblast. Immunovant's average media sentiment score of 0.79 beat Mesoblast's score of 0.34 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MESO or LNTH?

Lantheus has a consensus price target of $101.86, indicating a potential downside of 3.94%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Lantheus 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has better valuation and earnings, MESO or LNTH?

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 115.76 -$102.14M -$0.54 N/A Lantheus $1.54B 4.48 $233.56M $4.15 25.55

Is MESO or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Lantheus 18.05% 29.32% 15.00%

Does the media favor MESO or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for Mesoblast. Lantheus' average media sentiment score of 0.46 beat Mesoblast's score of 0.34 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MESO or LEGN?

Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 105.57%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Legend Biotech 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media favor MESO or LEGN?

In the previous week, Legend Biotech had 5 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.34 beat Legend Biotech's score of 0.18 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MESO or RYTM?

Rhythm Pharmaceuticals has a consensus target price of $133.13, indicating a potential upside of 25.36%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Rhythm Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.83

Does the media favor MESO or RYTM?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Mesoblast. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Mesoblast's score of 0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mesoblast (MESO) Competitors

$15.38 -0.12 (-0.77%)

As of 04:00 PM Eastern

Compare

MESO vs. KYMR, IMVT, LNTH, LEGN, and RYTM

Should you buy Mesoblast stock or one of its competitors? MarketBeat compares Mesoblast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mesoblast include Kymera Therapeutics (KYMR), Immunovant (IMVT), Lantheus (LNTH), Legend Biotech (LEGN), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Mesoblast compare to Kymera Therapeutics?

Mesoblast (NASDAQ:MESO) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Kymera Therapeutics had 16 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for Kymera Therapeutics and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.34 beat Kymera Therapeutics' score of -0.12 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Mesoblast has higher earnings, but lower revenue than Kymera Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	115.76	-$102.14M	-$0.54	N/A
Kymera Therapeutics	$39.21M	206.12	-$311.35M	-$3.57	N/A

Mesoblast has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Mesoblast's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kymera Therapeutics has a consensus target price of $117.14, indicating a potential upside of 19.22%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Mesoblast beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Mesoblast (NASDAQ:MESO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

Immunovant presently has a consensus target price of $37.33, indicating a potential downside of 0.76%. Given Immunovant's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunovant is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Mesoblast	N/A	N/A	N/A

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Mesoblast	$17.20M	115.76	-$102.14M	-$0.54	N/A

In the previous week, Immunovant had 1 more articles in the media than Mesoblast. MarketBeat recorded 2 mentions for Immunovant and 1 mentions for Mesoblast. Immunovant's average media sentiment score of 0.79 beat Mesoblast's score of 0.34 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mesoblast beats Immunovant on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Lantheus?

Mesoblast (NASDAQ:MESO) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	115.76	-$102.14M	-$0.54	N/A
Lantheus	$1.54B	4.48	$233.56M	$4.15	25.55

Mesoblast has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has a consensus price target of $101.86, indicating a potential downside of 3.94%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Lantheus had 3 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for Mesoblast. Lantheus' average media sentiment score of 0.46 beat Mesoblast's score of 0.34 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Summary

Lantheus beats Mesoblast on 13 of the 17 factors compared between the two stocks.

How does Mesoblast compare to Legend Biotech?

Mesoblast (NASDAQ:MESO) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Mesoblast has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	115.76	-$102.14M	-$0.54	N/A
Legend Biotech	$1.14B	4.78	-$296.80M	-$0.68	N/A

In the previous week, Legend Biotech had 5 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.34 beat Legend Biotech's score of 0.18 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Mesoblast's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Legend Biotech	-21.98%	-24.92%	-14.87%

Mesoblast has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 105.57%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Mesoblast beats Legend Biotech on 11 of the 17 factors compared between the two stocks.

How does Mesoblast compare to Rhythm Pharmaceuticals?

Mesoblast (NASDAQ:MESO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Mesoblast has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Mesoblast has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	115.76	-$102.14M	-$0.54	N/A
Rhythm Pharmaceuticals	$189.76M	38.35	-$196.54M	-$3.13	N/A

1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Mesoblast. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Mesoblast's score of 0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a consensus target price of $133.13, indicating a potential upside of 25.36%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Mesoblast has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Mesoblast's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Mesoblast beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-28.48	19.75	24.92	23.98
Price / Sales	115.76	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.29	8.29	10.79	6.50
Net Income	-$102.14M	$23.85M	$3.56B	$336.88M
7 Day Performance	11.85%	5.21%	1.67%	-0.22%
1 Month Performance	1.18%	2.19%	0.43%	0.77%
1 Year Performance	51.38%	60.99%	32.84%	31.57%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	1.2503 of 5 stars	$15.38 -0.8%	N/A	+48.5%	$2.01B	$17.20M	N/A	80	Gap Down
KYMR Kymera Therapeutics	1.9089 of 5 stars	$86.19 +0.7%	$117.14 +35.9%	+116.8%	$7.06B	$39.21M	N/A	170	Trending News Insider Trade
IMVT Immunovant	1.7671 of 5 stars	$32.81 -1.9%	$37.33 +13.8%	+141.1%	$6.86B	N/A	N/A	120
LNTH Lantheus	2.9347 of 5 stars	$105.38 +0.7%	$101.86 -3.3%	+34.1%	$6.85B	$1.54B	25.36	1,193
LEGN Legend Biotech	4.4006 of 5 stars	$34.62 -2.4%	$60.23 +74.0%	-13.7%	$6.52B	$1.03B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. KYMR, IMVT, LNTH, LEGN, and RYTM

How does Mesoblast compare to Kymera Therapeutics?

Summary

How does Mesoblast compare to Immunovant?

Summary

How does Mesoblast compare to Lantheus?

Summary

How does Mesoblast compare to Legend Biotech?

Summary

How does Mesoblast compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. KYMR, IMVT, LNTH, LEGN, and RYTM

How does Mesoblast compare to Kymera Therapeutics?

Do insiders & institutionals believe in MESO or KYMR?

Does the media favor MESO or KYMR?

Which has more risk & volatility, MESO or KYMR?

Which has preferable earnings and valuation, MESO or KYMR?

Is MESO or KYMR more profitable?

Do analysts recommend MESO or KYMR?

Summary

How does Mesoblast compare to Immunovant?

Which has more volatility & risk, IMVT or MESO?

Do analysts rate IMVT or MESO?

Is IMVT or MESO more profitable?

Do institutionals & insiders believe in IMVT or MESO?

Which has stronger valuation & earnings, IMVT or MESO?

Does the media prefer IMVT or MESO?

Summary

How does Mesoblast compare to Lantheus?

Which has better valuation and earnings, MESO or LNTH?

Which has more risk and volatility, MESO or LNTH?

Do institutionals and insiders believe in MESO or LNTH?

Do analysts rate MESO or LNTH?

Does the media favor MESO or LNTH?

Is MESO or LNTH more profitable?

Summary

How does Mesoblast compare to Legend Biotech?

Which has preferable earnings & valuation, MESO or LEGN?

Does the media favor MESO or LEGN?

Is MESO or LEGN more profitable?

Which has more volatility and risk, MESO or LEGN?

Do analysts recommend MESO or LEGN?

Do insiders and institutionals believe in MESO or LEGN?

Summary

How does Mesoblast compare to Rhythm Pharmaceuticals?

Which has more volatility & risk, MESO or RYTM?

Which has stronger valuation & earnings, MESO or RYTM?

Do insiders & institutionals believe in MESO or RYTM?

Does the media favor MESO or RYTM?

Do analysts recommend MESO or RYTM?

Is MESO or RYTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools